chenodeoxycholic acid has been researched along with Diseases, Metabolic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J; Gonzalez, FJ; Sun, L | 1 |
| Hao, H; He, Q; Wang, G; Wang, H; Xu, X | 1 |
| Gong, JY; Lu, Y; Setchell, KD; Wang, JS; Zhang, MH; Zhao, J | 1 |
| Wang, HJ; Wang, XH; Xie, XB; Yang, TJ; Yao, WL; Yu, H | 1 |
| Baldelli, F; Bifulco, G; Cipriani, S; Fiorucci, S; Mencarelli, A; Zampella, A | 1 |
3 review(s) available for chenodeoxycholic acid and Diseases, Metabolic
| Article | Year |
|---|---|
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
Topics: Animals; Antineoplastic Agents; Bile Acids and Salts; Biomarkers; Chenodeoxycholic Acid; Gastrointestinal Agents; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Metabolic Diseases; Mice; Receptors, Cytoplasmic and Nuclear; Signal Transduction | 2021 |
FXR modulators for enterohepatic and metabolic diseases.
Topics: Animals; Chenodeoxycholic Acid; Drug Design; Humans; Ligands; Liver Diseases; Metabolic Diseases; Patents as Topic; Receptors, Cytoplasmic and Nuclear | 2018 |
[Clinical features of a Chinese infant with inborn error of bile acid metabolism-3β-hydroxy-Δ(5)-C27-steroid dehydrogenase deficiency and review of the literature].
Topics: 3-Hydroxysteroid Dehydrogenases; Administration, Oral; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholestasis, Intrahepatic; DNA Mutational Analysis; Humans; Infant; Liver; Liver Function Tests; Male; Metabolic Diseases; Molecular Sequence Data; Mutation; Retrospective Studies | 2013 |
2 other study(ies) available for chenodeoxycholic acid and Diseases, Metabolic
| Article | Year |
|---|---|
Δ4-3-oxosteroid-5β-reductase deficiency: Responses to oral bile acid therapy and long-term outcomes.
Topics: Administration, Oral; Chenodeoxycholic Acid; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents; Humans; Infant, Newborn; Male; Metabolic Diseases; Mutation; Oxidoreductases; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
Topics: Animals; Chenodeoxycholic Acid; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Liver Diseases; Metabolic Diseases; Receptors, Cytoplasmic and Nuclear | 2011 |